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RECALLS
 PharmaTech LLC Issues Voluntary Nationwide Recall Due to Potential
Risk of Product Contamination
http://www.fda.gov/Safety/Recalls/ucm515610.htm?source=govdelivery&utm_medium=email&
utm_source=govdelivery
08/08/2016 Multiple brands Liquid Drug Products
Due to potential
Burkholderia
cepacia
contamination
PharmaTech, LLC
08/05/2016 Hospira
0.25% BUPIVACAINE
HYDROCHLORIDE
INJECTION, USP
Due to the presence
of particulate matter Hospira
08/02/2016 TevaPharmaceuticals
Amikacin Sulfate Injection
USP
Due to potential
contamination with
glass particulate
matter
Teva
Pharmaceuticals
08/01/2016 Comfort Shield Barrier Cream Cloths
Due to product
contamination with
Burkholderia
cepacia
Sage Products
07/21/2016 Talon CompoundingPharmacy (TCP) HCG and Sermorelin
Lack of sterility
assurance
Talon
Compounding
Pharmacy (TCP)
07/15/2016 Rugby Diocto Liquid, docusatesodium solution
Burkholderia
cepacia
contamination
PharmaTech LLC
SHORTAGES
 Current and resolved drug shortages and discontinuations reported to the FDA - July 6,
2016
*Note: Only those vaccines included on the recommended childhood and adolescent immunization
schedule are included in this update.
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Vaccines are listed in order used for the Childhood and Adolescent Immunization Schedule.
National Vaccine Supply Shortages
Vaccine Shortage Temporary Change From RoutineRecommendation
Hepatitis B No
Rotavirus No
Diphtheria, Tetanus, & Pertussis (DTaP and
Tdap) See note
2 See current information about Pentacel[4 pages]
Dec 2015
Td No
Haemophilus influenzae type B (Hib) No
Pneumococcal Conjugated (PCV) No
Pneumococcal Polysaccharide (PPV) No
Inactivated Polio (IPV) No
Measles, Mumps, & Rubella (MMR) See note
1 See Q&As about monovalent M-M-R vaccines Oct
2009
Influenza No See current information about influenza
Varicella/Zoster No
Hepatitis A No
Conjugated Meningococcal (MCV4) No
Human Papillomavirus (HPV) No
Note1: Based on input from the ACIP, professional societies, scientific leaders, and customers on October 26, 2009 Merck announced the
company has decided not to resume production of ATTENUVAX® (Measles Virus Vaccine Live), MUMPSVAX® (Mumps Virus
Vaccine Live), and MERUVAX®II (Rubella Virus Vaccine Live). This science-based decision will support vaccination of the largest
group of appropriate individuals. Updated Jan 2010
Note2: Sanofi Pasteur is experiencing a manufacturing delay with Pentacel (DTaP-IPV/Hib) vaccine, which is anticipated to result in
constrained supplies that will extend into the second half of 2016. However, Sanofi Pasteur has sufficient supplies of the relevant single
antigen vaccines (DAPTACEL, ActHIB, and IPOL) to address the anticipated gap in Pentacel supply. Updated Jul 2016
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FDA shortages
Generic Name or Active Ingredient Status
Acetohydroxamic Acid (Lithostat) Tablets Currently in Shortage
Ammonium Chloride Injection Currently in Shortage
Anagrelide Hydrochloride Capsules Currently in Shortage
Aprepitant (Emend) Capsules Resolved
Atropine Sulfate Injection Currently in Shortage
Azathioprine Tablet Resolved
Bleomycin Sulfate for Injection Currently in Shortage
Caffeine Anhydrous (125mg/mL); Sodium Benzoate (125mg/mL)
Injection Currently in Shortage
Calcium Chloride Injection, USP Currently in Shortage
Calcium Gluconate Injection Currently in Shortage
Cefazolin Injection Resolved
Cefepime Injection Currently in Shortage
Cefotaxime Sodium (Claforan) Injection Currently in Shortage
Cefotetan Disodium Injection Currently in Shortage
Ceftazidime and Avibactam (AVYCAZ) for Injection, 2.5g Currently in Shortage
Chloramphenicol Sodium Succinate Injection Currently in Shortage
Chloroquine Phosphate Tablets Resolved
Desmopressin Acetate Injection Currently in Shortage
Dexamethasone Sodium Phosphate Injection Currently in Shortage
Dextrose 5% Injection Bags Currently in Shortage
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Generic Name or Active Ingredient Status
Dextrose Injection USP, 70% Currently in Shortage
Dihydroergotamine Mesylate Injection Currently in Shortage
Disopyramide Phosphate (Norpace) Capsules Currently in Shortage
Doxorubicin (Adriamycin) Injection Resolved
Doxorubicin Lyophilized Powder for Injection Currently in Shortage
Epinephrine Injection Currently in Shortage
Eptifibatide (Integrilin) Injection Resolved
Estradiol Valerate Injection, USP Currently in Shortage
Ethiodized Oil (Lipiodol) Injection Currently in Shortage
Fentanyl Citrate (Sublimaze) Injection Currently in Shortage
Fomepizole Injection Currently in Shortage
Gemifloxacin Mesylate (Factive) Tablets Currently in Shortage
Haloperidol Lactate Injection Resolved
Imipenem and Cilastatin for Injection, USP Currently in Shortage
Indigotindisulfonate Sodium (Indigo Carmine) Injection Currently in Shortage
Ketorolac Tromethamine Injection Resolved
L-Cysteine Hydrochloride Injection Currently in Shortage
Leucovorin Calcium Lyophilized Powder for Injection Currently in Shortage
Leuprolide Acetate Injection Currently in Shortage
Levetiracetam (Keppra) Injection Resolved
Lidocaine Hydrochloride (Xylocaine) Injection Currently in Shortage
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Generic Name or Active Ingredient Status
LifeCare PCA™ Sterile Empty Vial and Injector Currently in Shortage
Liotrix (Thyrolar) Tablets Currently in Shortage
Mecasermin [rDNA origin] (Increlex) Injection Currently in Shortage
Memantine Hydrochloride (Namenda) XR Capsules Resolved
Meropenem for Injection, USP Resolved
Methyldopate Hydrochloride Injection Currently in Shortage
Methylphenidate Hydrochloride ER Capsules/Tablets Resolved
Methylprednisolone Sodium Succinate for Injection, USP Currently in Shortage
Metoprolol Injection Resolved
Morphine Sulfate Injection, USP, CII, (Preservative-Free)(For PCA Use
Only) Currently in Shortage
Multi-Vitamin Infusion (Adult and Pediatric) Currently in Shortage
Mupirocin Calcium Nasal Ointment Currently in Shortage
Nebivolol (BYSTOLIC) Tablets Resolved
Nimodipine (Nymalize) Oral Solution Currently in Shortage
Penicillin G Benzathine (Bicillin L-A) Injection Currently in Shortage
Peritoneal Dialysis Solutions Currently in Shortage
Phentolamine Mesylate Injection Resolved
Piperacillin and Tazobactam (Zosyn) Injection Currently in Shortage
Potassium Acetate Injection, USP Resolved
Potassium Chloride Injection Currently in Shortage
Reserpine Tablets Currently in Shortage
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Generic Name or Active Ingredient Status
Sacrosidase (Sucraid) Oral Solution Currently in Shortage
Sodium Acetate Injection, USP Currently in Shortage
Sodium Bicarbonate Injection, USP Currently in Shortage
Sodium Chloride 0.9% Injection Bags Currently in Shortage
Sodium Chloride 23.4% Injection Currently in Shortage
Sufentanil Citrate (Sufenta) Injection Currently in Shortage
Sumatriptan (Imitrex) Nasal Spray Currently in Shortage
Technetium Tc99m Succimer Injection (DMSA) Currently in Shortage
Theophylline Extended Release Tablets and Capsules Currently in Shortage
Tigecycline (Tygacil) Injection Currently in Shortage
Tiopronin (Thiola) Resolved
Tobramycin Injection Currently in Shortage
Tretinoin Capsules Currently in Shortage
Triamcinolone Hexacetonide Injectable Suspension (Aristospan) Currently in Shortage
Trimipramine Maleate (SURMONTIL) Capsules Currently in Shortage
Vancomycin Hydrochloride for Injection, USP Currently in Shortage
DRUG
 FDA Approves New GLP-1 Receptor Agonist Adlyxin for Diabetes
http://www.pharmacytimes.com/product-news/fda-approves-new-glp-1-receptor-agonist-
adlyxin-for-
diabetes?utm_source=Informz&utm_medium=Pharmacy+Times&utm_campaign=PT%5FBrea
king%5FNews%5F7%2D28%2D16
 FDA approves Lupin’s generic Klor-Con August 11, 2016
http://www.drugstorenews.com/article/fda-approves-lupins-generic-klor-con
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 Generic Dexedrine from Mylan Now Available
http://www.pharmacytimes.com/product-news/generic-dexedrine-from-mylan-now-
available?utm_source=Informz&utm_medium=Pharmacy+Times&utm_campaign=PT%5FeNe
ws%5FDaily%5FUnsponsored%5F8%2D9%2D16
HOSPITAL
 CMS star ratings sneak peek shows rating system favors smaller
hospitals with lower-risk patients
http://www.fiercehealthcare.com/healthcare/cms-star-ratings-favor-smaller-hospitals-lower-risk-
patients?utm_medium=nl&utm_source=internal&mrkid=799132&mkt_tok=eyJpIjoiTnpnM1lUU
TBaV0pqTlROaiIsInQiOiI4S3lQVVVHKzc5RWxSNFhvUldCcnVCdEJHK0N4ZVBCTVwvXC90
MnpyU3psaUNrTXFRa01QWWx0cDRtRFdxVGRBR3NQSjJkYTR2QTVkYW1qazlncU82M1pl
WEdYQTdwZFFoMkxnZzhONnMweFFZPSJ9
 Micro-hospital' model could help underserved populations
http://www.fiercehealthcare.com/healthcare/micro-hospital-model-could-help-underserved-
populations?utm_medium=nl&utm_source=internal&mrkid=799132&mkt_tok=eyJpIjoiTnpnM1l
UUTBaV0pqTlROaiIsInQiOiI4S3lQVVVHKzc5RWxSNFhvUldCcnVCdEJHK0N4ZVBCTVwvXC
90MnpyU3psaUNrTXFRa01QWWx0cDRtRFdxVGRBR3NQSjJkYTR2QTVkYW1qazlncU82M1
plWEdYQTdwZFFoMkxnZzhONnMweFFZPSJ9
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FDA
 Latest Drug Safety Podcast
The FDA Drug Safety Podcasts are produced by FDA's Center for Drug Evaluation and
Research (CDER). They provide emerging safety information about drugs in conjunction with
the release of Public Health Advisories and other drug safety issues.
FDA updates warnings for oral and injectable fluoroquinolone
antibiotics due to disabling side effects
July 26,
2016 Run Time:00:3:00
Transcript
FDA strengthens kidney warnings for diabetes medicines
canagliflozin (Invokana, Invokamet) and dapagliflozin (Farxiga,
Xigduo XR)
June 14,
2016 Run Time:00:3:04
Transcript
Update: FDA evaluating the risk of burns and scars with Zecuity
(sumatriptan) migraine patch
June 10,
2016 Run Time:00:1:12
Transcript
FDA warns about serious heart problems with high doses of the
antidiarrheal medicine loperamide (Imodium), including from
abuse and misuse
June 7,
2016 Run Time:00:3:00
Trans
 3 Federal Regulatory Changes Affecting Pharmacy
http://www.pharmacytimes.com/contributor/eric-roath-pharmd/2016/07/3-federal-regulatory-changes-
affecting-pharmacy/P-1#sthash.dovkC2xj.dpuf
http://www.pharmacytimes.com/contributor/eric-roath-pharmd/2016/07/3-federal-regulatory-changes-
affecting-pharmacy/P-3
 Your Child's First Vaccines
http://www.cdc.gov/vaccines/hcp/vis/vis-statements/multi.html
 Regulatory Reconnaissance
http://www.raps.org/SearchRegFocus.aspx?tag=Regulatory%20Reconnaissance&utm_source
=Email&utm_medium=Informz&utm_campaign=RF%2DToday
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 FDA Announces Major Change in Pharmacy Inspections
On July 12, FDA issued a notice announcing that it is changing its procedure for inspections of
human drug compounders. Starting August 1, FDA inspectors will make a preliminary
assessment of whether pharmacies are in compliance with 503A before applying 503B
standards in “Form FDA-483” investigations and will not include observations in its Form-483
based “solely” on FDA’s good manufacturing practice (CGMP) requirements under 503B,
unless it appears that pharmacies are compounding drugs that do not qualify for the 503A
exemptions. However, FDA will still undertake inspections of 503A facilities, rather than
complying with current statute and still intends to include CGMPs on Form FDA-483s,
potentially for 503A pharmacies. APhA is working to clarify what factors FDA will use in the
preliminary assessments; what standard FDA will use to determine “insanitary conditions”;
what steps FDA will follow when it determines a pharmacy is a 503A; and to increase FDA’s
communications on the status of inspections and enforcement actions with pharmacies and
State Boards of Pharmacy.
 APhA Responds to FDA Draft Compounding Guidances
In April, FDA issued three draft guidance documents related to compounding. After consulting
with our Compounding Work Group and APhA membership, on July 18th, APhA commented
on two of them (Prescription Requirement under 503A, Hospital and Health System
Compounding). The first guidance would prohibit compounding for office use under 503A,
further restrict the quantity that can be compounded in advance of a patient-specific
prescription, overestimate the ability of 503B facilities to meet patient compounding needs, and
attempt to define what constitutes a valid prescription. The second guidance would allow
hospitals and health systems to distribute compounded drug products, without patient-specific
prescriptions, for up to a 1-mile radius from their pharmacy within their own facilities. APhA
urged FDA to return to its previous interpretation of 503A and allow pharmacists to continue
compounding medications, without patient-specific prescriptions, for office use.
Draft Guidance Documents Seek to Restrict Compounders from Making Copies of
Commercially Available Drugs
On July 7, FDA issued two draft guidance documents (one for 503A and one for 503B
facilities) describing how it will restrict the compounding of drugs that are essentially copies of
commercially available or approved drugs. In the 503A draft guidance, FDA intends to consider
a compounded drug product to be “essentially a copy of a commercially available drug,” if the
compounded drug has the same active pharmaceutical ingredient(s) (API) as two or more
commercially available drugs; API(s) have the same, similar, or an easily substitutable dosage
strength and the commercially available drug can be administered used by the same route as
prescribed for the compounded drug—unless a prescriber determines that there is a change
made for an identified individual patient which produces a significant difference for that patient
from the commercially available drug; and/or the drug cannot be compounded regularly (the
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drug is on a drug shortage list or the compounder fills four or fewer prescriptions for the
relevant compounded drug in a calendar month). APhA is obtaining member feedback and
plans on submitting comments.
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IMMUNIZATIONS
 Current Vaccine Shortages & Delays
http://www.cdc.gov/vaccines/hcp/clinical-resources/shortages.html
INSURANCE
 Insurers restricting high-risk opioid users to select pharmacies
http://drugtopics.modernmedicine.com/drug-topics/news/insurers-restricting-high-risk-opioid-
users-select-pharmacies
CMS Proposes Sweeping 'Episode Payment Models' for Cardiac Care, Hip/Femur Fracture
Cases, Plus Changes to 'Comprehensive Care for Joint Replacement' Model
http://www.jdsupra.com/legalnews/cms-proposes-sweeping-episode-payment-61655/
 Medicare Advantage Value-Based Insurance Design Model
https://innovation.cms.gov/initiatives/vbid/
NEWS
 Pedal Away From Type 2 Diabetes - Study finds biking may help
adults avoid the blood sugar disorder
https://medlineplus.gov/news/fullstory_159835.html
Dietary Mineral Could Be One Key to Blood Pressure Control by: Jonathan Goodman - June
28, 2016
https://medlineplus.gov/news/fullstory_159836.html
 Survivors of Adult-onset Cancer Treated With Cisplatin Should Have
Routine Auditory Exams
http://www.cancertherapyadvisor.com/general-oncology/adult-onset-cancer-survivor-cisplatin-
routine-auditory-exam-risk/article/506155/?DCMP=ILC-
CTA_Promo_071116&cpn=&hmSubId=&hmEmail=zc9AEZF4x4rPbtLJAxJhmklDzcJVA8s10&
NID=&dl=0&spMailingID=14938215&spUserID=NDgyNTEwMTE5NjYS1&spJobID=820818894
&spReportId=ODIwODE4ODk0S0
 Tools to make your headache visits more efficient
http://www.medscape.com/infosite/197100.1/article-4?cp_available=true&src=1_invn_U_N
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SMP Medication Safety Alert! July 28, 2016 | Volume 21 | Issue 15
http://www.ismp.org/newsletters/acutecare/issues/20160728.pdf
Could CoQ10 Benefit Heart Failure Patients?
http://www.pharmacytimes.com/resource-centers/heart-failure/could-coq10-benefit-heart-failure-
patients?utm_source=Informz&utm_medium=Pharmacy+Times&utm_campaign=PT%5FeNews%5FDail
y%5FNCPA%5Fbarter%5F8%2D10%2D16
Retail 2027
http://www.drugstorenews.com/retail-health-0?tp=i-H55-Q5U-1Or-1Z2hR-1v-wGU-1c-KVJ-
1Z1Bk-
sebVl&utm_campaign=RetailClinician&utm_source=Experian&utm_medium=email&cid=5385&
mid=23128197
Obesity May Be Bad for the Brain, Too
https://medlineplus.gov/news/fullstory_160349.html
Study: Meat and Sugar Contribute Equally to Obesity
http://www.consultant360.com/exclusives/study-meat-and-sugar-contribute-equally-obesity
DASH Diet May Help To Prevent Gout Flares
http://www.consultant360.com/exclusives/dash-diet-may-help-prevent-gout-flares
Could Eating More Nuts Reduce Inflammation?
http://www.consultant360.com/exclusives/higher-consumption-nuts-may-reduce-inflammation
 Heater-Cooler Devices
Heater-cooler devices are often necessary for use during surgeries to warm or cool patients
http://www.fda.gov/MedicalDevices/ProductsandMedicalProcedures/CardiovascularDevices/H
eater-CoolerDevices/ucm20082725.htm
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 Guest blog: More members of Congress pressure Medicare on DIR
fees
http://www.drugstorenews.com/article/guest-blog-more-members-congress-pressure-medicare-dir-
fees?tp=i-H55-Q5U-1Pb-1aTi5-1v-wGU-1c-KgI-1aTQf-
ZEMil&utm_campaign=Daily&utm_source=Experian&utm_medium=email&cid=5431&mid=2347035
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 Fake Xanax Cut With Potent Pain Med Can Be a Killer
o 1 person died, 8 were sickened when illicit pills circulated in San Francisco, doctors report
o https://medlineplus.gov/news/fullstory_160329.html
